在神经退行性疾病中,黑色素组合和基于黑色素的混合分子的保护性活性
Francesca Galvani1, Mariarosaria Cammarota2, Federica Vacondio1
1Department of Food and Drug, University of Parma, Parma, Italy.
Journal of pineal research
|November 25, 2024
概括
黑色素组合显示出对神经退行性疾病 (如阿尔茨海默氏症和帕金森症) 的治疗潜力. 为了成功的临床转化,需要对协同机制和最佳剂量进行进一步的研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 神经退行性疾病 (阿尔茨海默氏症,帕金森症,多发性硬化症) 具有渐进性的残疾特征.
- 氧化应激,线粒体功能障碍和炎症是关键的致病途径.
- 在神经退行性疾病中,黑色素水平下降,影响睡眠和废物清除.
研究的目的:
- 审查黑激素在神经退行性疾病中的保护作用和治疗影响.
- 为了检查黑激素组合和混合分子的疗效.
- 以突出争议和未来的方向,以黑激素为基础的疗法.
主要方法:
- 关于黑色素及其组合的临床前和临床研究的文献综述.
- 对阿尔茨海默病,帕金森病和多发性硬化症的体外和动物模型的分析.
- 单剂与组合黑激素治疗的比较.
主要成果:
- 黑色素表现出细胞保护性质,可以抵抗神经炎症.
- 临床前研究显示出有希望的结果,但临床结果通常是温和的或差的.
- 黑色素组合和混合分子在临床前模型中显示出潜力.
结论:
- 黑色素组合可能为多因素神经退行性疾病提供协同效益.
- 最佳剂量,分子标和毒性仍然是有争议的领域.
- 需要进一步的研究来阐明临床翻译的协同机制.
相关概念视频
Management of Insomnia
231
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
231
Sedatives and Hypnotics Drugs: Miscellaneous Agents
146
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
146
Sedatives and Hypnotics: Overview
279
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
279
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


